Suppr超能文献

相似文献

1
Inhibition of bradykinin receptor B1 protects mice from focal brain injury by reducing blood-brain barrier leakage and inflammation.
J Cereb Blood Flow Metab. 2010 Aug;30(8):1477-86. doi: 10.1038/jcbfm.2010.28. Epub 2010 Mar 3.
3
Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking.
J Autoimmun. 2011 Mar;36(2):106-14. doi: 10.1016/j.jaut.2010.11.004. Epub 2011 Jan 8.
4
Blocking of bradykinin receptor B1 protects from focal closed head injury in mice by reducing axonal damage and astroglia activation.
J Cereb Blood Flow Metab. 2012 Sep;32(9):1747-56. doi: 10.1038/jcbfm.2012.62. Epub 2012 May 9.
7
Effect of the bradykinin 1 receptor antagonist SSR240612 after oral administration in Mycobacterium tuberculosis-infected mice.
Tuberculosis (Edinb). 2018 Mar;109:1-7. doi: 10.1016/j.tube.2018.01.003. Epub 2018 Feb 2.
8
Primary Role for Kinin B and B Receptors in Glioma Proliferation.
Mol Neurobiol. 2017 Dec;54(10):7869-7882. doi: 10.1007/s12035-016-0265-9. Epub 2016 Nov 16.
9
Selective kinin receptor agonists as cardioprotective agents in myocardial ischemia and diabetes.
J Pharmacol Exp Ther. 2013 Jul;346(1):23-30. doi: 10.1124/jpet.113.203927. Epub 2013 Apr 16.

引用本文的文献

1
Whole patient knowledge modeling of COVID-19 symptomatology reveals common molecular mechanisms.
Front Mol Med. 2023 Jan 4;2:1035290. doi: 10.3389/fmmed.2022.1035290. eCollection 2022.
2
Delayed plasma kallikrein inhibition fosters post-stroke recovery by reducing thrombo-inflammation.
J Neuroinflammation. 2024 Jun 13;21(1):155. doi: 10.1186/s12974-024-03149-w.
4
Neprilysin inhibitors and risk of Alzheimer's disease: A future perspective.
J Cell Mol Med. 2024 Jan;28(2):e17993. doi: 10.1111/jcmm.17993. Epub 2023 Oct 17.
8
Nanoparticle-based drug delivery for the treatment of traumatic brain injury.
Expert Opin Drug Deliv. 2023 Jan;20(1):55-73. doi: 10.1080/17425247.2023.2152001. Epub 2022 Dec 6.
10
Targeting thromboinflammation in COVID-19 - A narrative review of the potential of C1 inhibitor to prevent disease progression.
Mol Immunol. 2022 Oct;150:99-113. doi: 10.1016/j.molimm.2022.08.008. Epub 2022 Aug 22.

本文引用的文献

1
The role of bradykinin B(1) and B(2) receptors for secondary brain damage after traumatic brain injury in mice.
J Cereb Blood Flow Metab. 2010 Jan;30(1):130-9. doi: 10.1038/jcbfm.2009.196. Epub 2009 Sep 23.
2
Differential effects of endothelin receptor A and B antagonism on cerebral hypoperfusion following traumatic brain injury.
Neurol Res. 2010 Mar;32(2):209-14. doi: 10.1179/174313209X414515. Epub 2009 Jun 30.
5
Combination therapies for traumatic brain injury: prospective considerations.
J Neurotrauma. 2009 Jun;26(6):925-39. doi: 10.1089/neu.2008.0794.
6
Pathophysiology of traumatic brain injury.
Mt Sinai J Med. 2009 Apr;76(2):97-104. doi: 10.1002/msj.20104.
8
Pharmacology of traumatic brain injury: where is the "golden bullet"?
Mol Med. 2008 Nov-Dec;14(11-12):731-40. doi: 10.2119/2008-00050.Beauchamp. Epub 2008 Aug 18.
9
Mechanisms of ET-1-induced endothelial dysfunction.
J Cardiovasc Pharmacol. 2007 Dec;50(6):621-8. doi: 10.1097/FJC.0b013e31813c6cc3.
10
The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?
Br J Pharmacol. 2008 Mar;153(6):1105-19. doi: 10.1038/sj.bjp.0707516. Epub 2007 Oct 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验